Literature DB >> 17977937

Transplant estimated function: a simple index to evaluate beta-cell secretion after islet transplantation.

Andrea Caumo1, Paola Maffi, Rita Nano, Federico Bertuzzi, Livio Luzi, Antonio Secchi, Ezio Bonifacio, Lorenzo Piemonti.   

Abstract

OBJECTIVE: The beta-score is a highly regarded approach to the assessment of transplant functionality. Our aim was to develop an index of beta-cell function that hinges on the pillars of the beta-score (daily insulin requirement and A1C), has a straightforward physiological interpretation, and does not require the execution of an insulin stimulation test. RESEARCH DESIGN AND METHODS: The new index is denoted transplant estimated function (TEF) and is obtained from the daily insulin requirement and A1C. TEF estimates the amount of insulin secreted daily and can be normalized to the number of transplanted islets, thus permitting evaluation of the cost-effectiveness of the transplant. TEF was compared with the area under the curve of C-peptide [AUC(C-pep)] concentration over 24 h, as well as the acute insulin response to intravenous glucose (AIR(glu)) and to arginine (AIR(arg)). The association between TEF and beta-score was also investigated.
RESULTS: The correlation of TEF with 24-h AUC(C-pep) was r = 0.73 (P < 0.005), whereas that for beta-score versus 24-h AUC(C-pep) was r = 0.33 (NS). The correlation of TEF with AIR(glu) was r = 0.59 (P < 0.001) and close to that for beta-score versus AIR(glu) (r = 0.65, P < 0.001). The correlation of TEF with AIR(arg) was r = 0.33 (P < 0.005) and was similar to that for beta-score versus AIR(arg) (r = 0.34, P < 0.005). TEF and beta-score were correlated well (r = 0.69, P < 0.0001) and showed similar time profiles.
CONCLUSIONS: TEF estimates daily insulin secretion, it is simpler than the beta-score, and its performance against reference indexes of beta-cell secretion is in line with that exhibited by beta-score. TEF can be normalized to the number of transplanted islets and thereby provides a benchmarking tool to evaluate the cost-effectiveness of the transplant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17977937     DOI: 10.2337/dc07-0975

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  10 in total

1.  CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.

Authors:  Antonio Citro; Elisa Cantarelli; Paola Maffi; Rita Nano; Raffaella Melzi; Alessia Mercalli; Erica Dugnani; Valeria Sordi; Paola Magistretti; Luisa Daffonchio; Pier Adelchi Ruffini; Marcello Allegretti; Antonio Secchi; Ezio Bonifacio; Lorenzo Piemonti
Journal:  J Clin Invest       Date:  2012-09-17       Impact factor: 14.808

2.  Residual β-Cell Function Predicts Clinical Response After Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Hang Xiang; Chao Yang; Tianyuan Xiang; Zheng Wang; Xin Ge; Fan Li; Yuehan Su; Haixu Chen; Xianyong Huang; Qiang Zeng
Journal:  Stem Cells Transl Med       Date:  2016-03-29       Impact factor: 6.940

3.  Regulation of the JNK3 signaling pathway during islet isolation: JNK3 and c-fos as new markers of islet quality for transplantation.

Authors:  Saida Abdelli; Klearchos K Papas; Kate R Mueller; Mike P Murtaugh; Bernhard J Hering; Christophe Bonny
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

4.  Validation of the BETA-2 Score: An Improved Tool to Estimate Beta Cell Function After Clinical Islet Transplantation Using a Single Fasting Blood Sample.

Authors:  S Forbes; R A Oram; A Smith; A Lam; T Olateju; S Imes; A J Malcolm; A M J Shapiro; P A Senior
Journal:  Am J Transplant       Date:  2016-04-21       Impact factor: 8.086

5.  Fasting parameters for estimation of stimulated β cell function in islet transplant recipients with or without basal insulin treatment.

Authors:  Bas S Uitbeijerse; Michiel F Nijhoff; Jacob K Sont; Eelco J P de Koning
Journal:  Am J Transplant       Date:  2020-07-13       Impact factor: 8.086

6.  Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation.

Authors:  Piotr J Bachul; Karolina Golab; Lindsay Basto; Steven Zangan; Jordan S Pyda; Angelica Perez-Gutierrez; Peter Borek; Ling-Jia Wang; Martin Tibudan; Dong-Kha Tran; Roi Anteby; Gabriela S Generette; Jędrzej Chrzanowski; Wojciech Fendler; Laurencia Perea; Kumar Jayant; Aaron Lucander; Celeste Thomas; Louis Philipson; J Michael Millis; John Fung; Piotr Witkowski
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

7.  Pancreatic islet transplantation.

Authors:  Maria Lúcia Corrêa-Giannella; Alexandre S Raposo do Amaral
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320

8.  Primary graft function, metabolic control, and graft survival after islet transplantation.

Authors:  Marie-Christine Vantyghem; Julie Kerr-Conte; Laurent Arnalsteen; Geraldine Sergent; Frederique Defrance; Valery Gmyr; Nicole Declerck; Violeta Raverdy; Brigitte Vandewalle; Pascal Pigny; Christian Noel; Francois Pattou
Journal:  Diabetes Care       Date:  2009-08       Impact factor: 19.112

9.  Diabetes mellitus: new challenges and innovative therapies.

Authors:  Cristina M Sena; Carla F Bento; Paulo Pereira; Raquel Seiça
Journal:  EPMA J       Date:  2010-03-13       Impact factor: 6.543

10.  Potential of protein phosphatase inhibitor 1 as biomarker of pancreatic β-cell injury in vitro and in vivo.

Authors:  Lei Jiang; Benedicte Brackeva; Zhidong Ling; Gertjan Kramer; Johannes M Aerts; Frans Schuit; Bart Keymeulen; Daniel Pipeleers; Frans Gorus; Geert A Martens
Journal:  Diabetes       Date:  2013-04-04       Impact factor: 9.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.